OTC$PTN
Palatin Technologies Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Palatin Technologies reported second quarter fiscal year 2021 financial results.
Palatin Technologies reported a net loss of $10.0 million, or $(0.04) per share, for the quarter ended December 31, 2020. The company had $72.2 million in cash and cash equivalents as of December 31, 2020. Vyleesi gross sales for the quarter amounted to $943,950, with product revenue of $(163,971), net of allowances and accruals.
- Positive results from Phase 2 clinical study of PL9643 in patients with Dry Eye Disease.
- Company continues to rebuild commercial infrastructure and brand awareness for Vyleesi.
- Cash and cash equivalents were approximately $72.2 million as of December 31, 2020.
- Vyleesi gross sales for the quarter ended December 31, 2020 amounted to $943,950 with product revenue of $(163,971) net of allowances and accruals.
Headline financials
Revenue & EPS history
Palatin Technologies · Revenue · Quarterly
-$164K
Forward guidance
Palatin is planning a Phase 2/3 Clinical trial with PL9643 for the treatment of DED targeted for mid-calendar year 2021 and a Phase 2 proof-of-concept clinical study with an oral formulation of PL8177 in ulcerative colitis patients is targeted to start mid-calendar year 2021, with data readout potentially in mid-calendar year 2022.
Tailwinds
- PL9643 is a novel approach to treating dry eye disease.
- PL9643 has a rapid therapeutic onset and excellent tolerability profile.
- The company is planning a Phase 2/3 study targeted for mid-calendar year 2021, with data readout in the first half of calendar year 2022 for PL9643.
- Payer reimbursement is rising.
- Month over month prescription numbers continuing through January 2021 are increasing.
Headwinds
- Statistical significance for the primary endpoints was not reached in the overall enrolled population that included mild, moderate, and severe patients, as measured at the 12-week primary evaluation visit.
- Phase 2 proof-of-concept clinical study with an oral formulation of PL8177 in ulcerative colitis patients has data readout potentially in mid-calendar year 2022.
- The company incurred a net loss for the quarter.
- Vyleesi product revenue was negative, net of allowances and accruals.
- Commercial expenses related to Vyleesi and to PL9643’s Phase 2 study for the treatment of dry eye disease increased the net loss.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
-2.4%
Avg return
Earnings day
-0.6%
Avg return
5 days after
-2.5%
Avg return
30 days after
31%
20 / 64 earnings
Positive
+36.4%
Q3 2026
Best reaction
-27.1%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.2% | +29.2% | +18.2% | |
| Q1 2026 | +0.0% | +27.8% | +152.3% | |
| Q3 2026 | +36.4% | +9.1% | -9.1% | |
| Q3 2025 | +22.2% | +55.6% | +11.1% | |
| Q2 2025 | +7.1% | +4.0% | -20.2% | |
| Q1 2025 | -21.5% | -21.8% | -26.1% | |
| Q4 2024 | -8.3% | -1.1% | +39.3% | |
| Q3 2024 | -15.4% | -15.4% | -24.5% | |
| Q2 2024 | -27.1% | -21.7% | -62.8% | |
| Q1 2024 | -1.0% | -2.5% | +31.3% | |
| Q4 2023 | -8.5% | +19.7% | +13.3% | |
| Q3 2023 | -5.8% | -3.1% | -13.9% | |
| Q2 2023 | -8.8% | -2.2% | -18.0% | |
| Q1 2023 | -9.0% | -5.8% | -25.7% | |
| Q4 2022 | -19.5% | -27.7% | -43.6% | |
| Q3 2022 | -7.7% | -10.3% | -28.2% | |
| Q2 2022 | +5.0% | +0.0% | +2.5% | |
| Q1 2022 | -2.5% | -10.0% | +35.0% | |
| Q4 2021 | -6.4% | -8.5% | -12.8% | |
| Q3 2021 | +9.8% | +13.4% | +10.4% | |
| Q2 2021 | -19.5% | -23.9% | -33.6% | |
| Q1 2021 | +7.3% | +2.4% | +4.9% | |
| Q4 2020 | +0.0% | -4.2% | -20.8% | |
| Q3 2020 | -2.2% | -2.2% | +30.4% | |
| Q2 2020 | -14.1% | -18.3% | -39.4% | |
| Q1 2020 | -4.9% | -2.5% | -1.2% | |
| Q4 2019 | +7.1% | +3.0% | -16.2% | |
| Q3 2019 | +2.2% | +7.9% | -10.1% | |
| Q2 2019 | +2.7% | +6.8% | +36.5% | |
| Q1 2019 | -10.8% | -17.2% | -21.5% | |
| Q4 2018 | -3.8% | -2.9% | -14.3% | |
| Q3 2018 | -4.6% | -7.6% | -22.9% | |
| Q2 2018 | +5.6% | +7.8% | +6.7% | |
| Q1 2018 | +0.0% | +8.7% | +10.0% | |
| Q4 2017 | -6.1% | +0.0% | +15.2% | |
| Q3 2017 | -12.8% | -10.6% | -25.5% | |
| Q2 2017 | -6.8% | -11.4% | -22.7% | |
| Q1 2017 | -5.5% | -5.5% | +1.8% | |
| Q4 2016 | -1.8% | +16.1% | -3.6% | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -7.7% | — | — | |
| Q4 2015 | -8.5% | — | — | |
| Q3 2015 | +1.1% | — | — | |
| Q2 2015 | +23.0% | — | — | |
| Q1 2015 | +4.0% | — | — | |
| Q4 2014 | -5.0% | — | — | |
| Q3 2014 | -2.6% | — | — | |
| Q2 2014 | -7.0% | — | — | |
| Q1 2014 | +15.3% | — | — | |
| Q4 2013 | -7.0% | — | — | |
| Q3 2013 | +1.6% | — | — | |
| Q2 2013 | -5.9% | — | — | |
| Q1 2013 | +7.9% | — | — | |
| Q4 2012 | -6.3% | — | — | |
| Q4 2010 | -6.3% | — | — | |
| Q3 2011 | +5.0% | — | — | |
| Q3 2012 | +5.0% | — | — | |
| Q2 2012 | -5.9% | — | — | |
| Q2 2011 | -5.9% | — | — | |
| Q1 2012 | -3.8% | — | — | |
| Q1 2011 | -3.8% | — | — | |
| Q4 2011 | -3.8% | — | — | |
| Q3 2010 | -9.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro